Therapeutic Potential of Phlorotannins

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Pharmacology".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 897

Special Issue Editors


E-Mail Website
Guest Editor
Center for Molecular Intelligence, The State University of New York, Korea, Incheon, Republic of Korea
Interests: phloroglucinol oligomers; phlorotrannins; eckols; pharmcology; anti-neurodegeneration; anti-aging; chemical synthesis
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Chemical and Biological Engineering, Hanbat National University, Dongseodaero 125, Yuseong‐gu, Daejeon 305‐719, Republic of Korea
Interests: natural product isolation; characterization; bioactivity; Alzheimer drug screening
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Center for Molecular Intelligence, The State University of New York, Korea, 119 Songdomunhwa-ro, Yeonsu-gu, Incheon 21985, Republic of Korea
Interests: anti-cancer; chemo-sensitizer; eckols; chemoprevention; bioactivity; phlorotannins
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue, titled "Therapeutic Potential of Phlorotannins", delves into the promising realm of phlorotannins. These compounds, primarily oligomers of phloroglucinol, have been increasingly recognized for their potent physiological activities. Produced mostly by brown algae as secondary metabolites with a variety of molecular structures, phlorotannins are capturing the interest of the healthcare industry due to their general safety and broad medicinal potential.

Over the last two decades, a substantial volume of both in vitro and in vivo research has demonstrated their various potential applications in mitigating a range of intractable diseases, as well as in improving unhealthy conditions. These include neurodegenerative disorders, various cancers, viral infections, and other chronic degenerative conditions. The unique structural attributes of phlorotannnins not only facilitate their biological activity but also offer expansive opportunities for chemical modification, making them prime candidates for future pharmaceutical developments as well as nutraceutical and cosmeceutical applications.

This Special Issue aims to enhance our understanding of a variety of phlorotannins from the perspective of healthcare science and technology. We invite scientists engaged in the study of phlorotannins to contribute their insights. Contributions may focus on analytical, physicochemical, synthetic, theoretical, or pharmacological aspects. Through research articles and reviews, we aspire to consolidate knowledge and foster innovation in the development of phlorotannins as competitive drugs, nutraceuticals, or cosmeceuticals. This Special Issue seeks to provide a comprehensive resource that will inform and inspire ongoing and future research in this exciting field.

Dr. Hyeon-Cheol Shin
Dr. Bong Ho Lee
Dr. Hye Jeong Hwang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • phlorotannin
  • analytical
  • physicochemical
  • synthetic
  • theoretical
  • pharmacological

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 1988 KiB  
Article
A Pharmacokinetic and Bioavailability Study of Ecklonia cava Phlorotannins Following Intravenous and Oral Administration in Sprague–Dawley Rats
by Hyeon-Cheol Shin, Clint Rosenfeld, Robert J. Guttendorf, Susan B. Wade, Yong Ju Park, Ju Hee Kim, Seong Ho Kim, Bong Ho Lee and Hye Jeong Hwang
Mar. Drugs 2024, 22(11), 500; https://doi.org/10.3390/md22110500 - 4 Nov 2024
Viewed by 689
Abstract
This study examines the pharmacokinetics and bioavailability of phlorotannins from Ecklonia cava in rats following intravenous and oral administration. Known for their potent antioxidant, anti-inflammatory and many other bioactivities, these phlorotannins, particularly dieckol, 8,8′-bieckol, and phlorofucofuroeckol-A (PFF-A), were analyzed using high-performance liquid chromatography [...] Read more.
This study examines the pharmacokinetics and bioavailability of phlorotannins from Ecklonia cava in rats following intravenous and oral administration. Known for their potent antioxidant, anti-inflammatory and many other bioactivities, these phlorotannins, particularly dieckol, 8,8′-bieckol, and phlorofucofuroeckol-A (PFF-A), were analyzed using high-performance liquid chromatography coupled with tandem mass spectrometry. Intravenous administration at 10 mg/kg allowed detectability in plasma for up to 36 h for dieckol and 8,8′-bieckol, but only 2 h for PFF-A. Oral administration at doses of 100 mg/kg and 1000 mg/kg showed limited detectability, indicating low bioavailability and rapid clearance, particularly for PFF-A. The pharmacokinetic data suggest non-linear increases in the maximum plasma concentration (Cmax) and area under the curve (AUC) with increasing doses, pointing to significant challenges in achieving systemic availability of these eckols through oral administration. This study underscores the necessity for advanced formulation strategies and alternative routes of administration to enhance systemic bioavailability. At the same time, this result also suggests their effects may be through non-systemic pathways such as gut microbiome modulation or lipid-rich tissue targeting. The findings lay a crucial foundation for the further development of Ecklonia cava phlorotannins as therapeutic agents, offering insights into their pharmacokinetic behavior and informing enhancements in future clinical utility. Full article
(This article belongs to the Special Issue Therapeutic Potential of Phlorotannins)
Show Figures

Graphical abstract

Back to TopTop